891782-61-9 Usage
Uses
Used in Pharmaceutical Industry:
3-PIPERAZIN-2-YL-PROPIONIC ACID is used as a potential therapeutic agent for the treatment of psychiatric disorders such as schizophrenia and bipolar disorder. Its structural similarity to GABA and its pharmacological properties suggest that it may help in managing the symptoms of these conditions by modulating neurotransmission.
Used in Neurological Research:
3-PIPERAZIN-2-YL-PROPIONIC ACID is utilized as a subject of study in the field of neurology, particularly for its antioxidant and neuroprotective effects. These properties make PZP a candidate for research into the prevention and treatment of neurodegenerative diseases, where oxidative stress and neuronal damage are significant factors.
Used in Drug Development:
3-PIPERAZIN-2-YL-PROPIONIC ACID is employed in the development of new drugs targeting the GABAergic system. Its potential as an anxiolytic and antipsychotic agent, along with its effects on neurotransmission, positions PZP as a valuable compound in the search for novel treatments for various neurological and psychiatric conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 891782-61-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,9,1,7,8 and 2 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 891782-61:
(8*8)+(7*9)+(6*1)+(5*7)+(4*8)+(3*2)+(2*6)+(1*1)=219
219 % 10 = 9
So 891782-61-9 is a valid CAS Registry Number.
891782-61-9Relevant academic research and scientific papers
Piwinski, John J.,Wong, Jesse K.,Green, Michael J.,Kaminski, James J.,Colizzo, Frank,Albanese, Margaret M.,Ganguly, Ashit K.,Billah, M. Motasim,Anthes, John C.,West Jr., Robert E.
, p. 3469 - 3474 (1998)
A series of N-acyl-4-(5,6-dihydro-11-H-benzo[5,6]cyclohepta[1,2- b]pyridin-11-ylidene)piperazines is described that are dual antagonists of PAF and histamine. The structural requirements for activity in this series parallel those of their previously reported piperidinylidene counterparts. Whereas their global minimum energy conformations are different for both series of compounds, computer assisted molecular modeling suggests that a common bioactive conformation is possible.
